42
Views
1
CrossRef citations to date
0
Altmetric
Articles

Development and Validation of a LC-MS/MS Method for the Determination of Valsartan in Human Plasma after Protein Precipitation or Liquid-Liquid Extraction

, &
Pages 504-517 | Received 16 May 2019, Accepted 13 Jul 2019, Published online: 06 Oct 2019
 

Abstract

A rapid and specific liquid chromatographic mass/mass (LC-MS/MS) method is described for the assessment of valsartan (VAL) in human plasma after protein precipitation (PPT) and liquid-liquid extraction (LLE) techniques. The column used in PPT method was Eclipse Plus column, (C18, 50 mm x 2.1 mm, 1.8 μm) with a mobile phase ratio of 0.1% formic acid: methanol (15:85, v/v) while the column used in LLE method was Agilent column, (C18, 50 mm x 4.6 mm, 5 μm) with a mobile phase ratio of 0.1 % formic acid: acetonitrile (20:80, v/v). The assay was found to be linear over the ranges of 20-10000 and 25-8000 ng/ mL VAL using the PPT and LLE, respectively. The developed method was validated following the united states food and drug administration (US - FDA) recommendations and directions from the European Medical Agency (EMA). The method was validated for sensitivity, selectivity, linearity, accuracy and precision, recovery, dilution integrity, matrix effect, carryover in the matrix, and analyte stability during both short- and long-term sample processing and storage.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.